Management of Excessive Oral Secretions

First-Line Treatment: Anticholinergic Medications

The American Thoracic Society recommends starting with an oral anticholinergic medication, such as glycopyrrolate or atropine, as first-line therapy, escalating to botulinum toxin injections if anticholinergics fail or cause intolerable side effects 1, 2
The National Comprehensive Cancer Network suggests beginning with an inexpensive oral anticholinergic agent and continuing only if benefits outweigh side effects 1, 3
Glycopyrrolate does not cross the blood-brain barrier effectively, reducing the risk of delirium compared to other anticholinergics 4
Atropine can be administered sublingually, providing a local effect with reduced systemic side effects 5, 6
Scopolamine patches may be used, but onset of benefit is approximately 12 hours, making them inappropriate for imminently dying patients 4, 5, 6

The American Thoracic Society recommends inject botulinum toxin into salivary glands for patients with inadequate response or intolerance to anticholinergics 1, 3
Botulinum toxin therapy is an inexpensive procedure with simple, minimally uncomfortable injections, providing lasting beneficial effects on salivary function 1, 2
The therapy is associated with viscous saliva and mild to moderate pain, and evidence quality is limited with undefined optimal doses 1, 2

In palliative care settings, glycopyrrolate dosing can be 0.2-0.4 mg IV or subcutaneously every 4 hours as needed, and should be part of comprehensive symptom management 5, 6, 7
The World Journal of Emergency Surgery suggests considering anticholinergics in patients with increased oral secretions in palliative care 7
Anticholinergics have a neutral risk-benefit balance because some patients achieve relief while others cannot tolerate side effects 1, 2

Glycopyrrolate can be administered via continuous IV or subcutaneous infusion for refractory cases, as part of comprehensive symptom management in palliative care, according to the National Comprehensive Cancer Network 8

In pediatric emergencies, atropine dosing must be weight-based with careful attention to minimum and maximum doses, as recommended by the American Heart Association 9

H2-receptor antagonists, such as famotidine 20 mg IV, or proton pump inhibitors can reduce secretions in specific contexts, such as gastric hypersecretion in short bowel syndrome, as suggested by Clinical Nutrition 10
Metoclopramide 10-20 mg IV can be used as a prokinetic agent to address secretion-related symptoms indirectly through antiemetic effects, according to the National Comprehensive Cancer Network 8
Ondansetron 4-8 mg IV can be used for nausea management, as recommended by the American Journal of Hematology and the National Comprehensive Cancer Network 8, 11